U.S. Petent and Trademark Office; U.S. DEI Under the Papervork Reduction Act of 1925, no persons are required to respond to a collection of information unless it contains

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10566495	
Filing Date		2006-01-31	
First Named Inventor Hiros		shi KANNAN	
Art Unit			
Examiner Name			_
Attorney Docket Numb	er	SUGI0162	

U.S.PATENTS									Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date Name of Patentee or of cited Document			Relev	s,Columns,L ant Passage es Appear			
	1										
If you wis	h to a	dd additional U.S. Pater							Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant		Relev	s,Columns,L ant Passage es Appear		
	1										
If you wisi	h to a	dd additional U.S. Publi		p		n information p		d butto	Add Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	,	Kind Code ⁴	Publication	Name of Patente Applicant of cited Document	e or	Pages,Colu where Rele Passages o Figures App	vant r Relevant	70
	1	8-334546	JP		A	1996-12-17	HITACHI LTD. KAWASAKI HEAVY IND				Z
	2	2001-175336	JP		A	2001-06-29					V
	3	2002-116824	JP		A	2002-04-19	ISHIKAWAJIMA HARIMA HEAVY I CO LTD	ND			V

		4	2000-240586	JP	A	2000-09-05	SOGO PUMP SEISAKUSHO:KK		✓
	If you wis	h to a	dd additional Foreign	Patent Document	citation	information p	lease click the Add butto	n Add	
				NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
	Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T6
1 International Search Report issued in the corresponding application PCTUP2004/010708 and completed September 17, 2004 and mailed October 5, 2004.							′ _		
	If you wis	h to a	dd additional non-pate	nt literature docu	ment ci	tation informat	ion please click the Add	button Add	
				E)	AMINE	D SIGNATIID	E		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at view.USPTO.QDV or MPEP 901.04. * Enter office that issued the document, by the Noveletor (WIPO Standard ST3.). * For Laplanese patent document, the antication of the year of the region for the Emperor warp precess the sent annument patent document. * And of coursent by the appropriate symbols as enducated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if Empirish targuages transitions in statched.*

Date Considered

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99) Filing Da Art Unit

Application Number		10566495
Filing Date		2006-01-31
First Named Inventor Hiros		hi KANNAN
Art Unit		
Examiner Name		
Attorney Docket Number		SUGI0162

CERTIFICATION STATEMENT

Please see 3	37	CFR	1.97	and	1.98 to	make	the	appropri	ate se	election(s)	ć
--------------	----	-----	------	-----	---------	------	-----	----------	--------	-----------	----	---

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c) for the contraction of th

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Joerg-Uwe Szipl/	Date (YYYY-MM-DD)	2006-05-01
Name/Print	Joerg-Uwe Szipi	Registration Number	31799

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 Gad 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1436, Alexandris, V.S. 2213.1-450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2. 2213.1-450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.